Anti-amyloid monoclonal antibodies represent a transformative approach to disease-modifying therapy for Alzheimer's disease (AD). These therapeutics target various forms of amyloid-beta (Aβ) plaques and oligomers, aiming to remove pathological amyloid deposits and slow cognitive decline. Four antibodies have undergone extensive clinical development: lecanemab, donanemab, gantenerumab, and solanezumab. This page provides a comprehensive comparison of their clinical trial designs, efficacy data, safety profiles, and patient selection criteria.
| Antibody | Target | Epitope | Manufacturer | FDA Status |
|---|---|---|---|---|
| Lecanemab (Leqembi) | Soluble Aβ protofibrils | Aβ protofibrils (3X42) | Eisai/Biogen | Approved 2023 |
| Donanemab (Kisunla) | Amyloid plaques | N3pG-Aβ (pyroglutamate) | Eli Lilly | Approved 2024 |
| Gantenerumab | Aggregated Aβ (plaques, oligomers) | Aβ plaques | Roche/Genentech | Discontinued |
| Solanezumab | Soluble Aβ monomers | Central Aβ domain | Eli Lilly | Failed |
Lecanemab selectively binds to soluble Aβ protofibrils, which are believed to be the most toxic form of amyloid species. Protofibrils are intermediate aggregates that are more soluble than plaques but exhibit high neurotoxicity. By targeting protofibrils, lecanemab can neutralize soluble toxic species while also promoting clearance of deposited plaques[1].
Donanemab preferentially binds to pyroglutamate-modified Aβ (N3pG-Aβ), an epitope that is enriched in deposited plaques rather than soluble monomers. This plaque-targeting mechanism leads to robust amyloid plaque removal through microglial-mediated phagocytosis[2].
Gantenerumab is a fully human IgG1 antibody that binds to aggregated Aβ in both oligomeric and fibrillar forms. It engages the Fcγ receptor pathway on microglia, triggering antibody-mediated phagocytosis of amyloid plaques[3].
Solanezumab was designed to bind to the central domain of soluble Aβ monomers, promoting peripheral clearance of Aβ from the brain. However, its failure to meaningfully clear plaques or slow cognitive decline in multiple Phase 3 trials suggests that targeting soluble monomers alone is insufficient for clinical benefit[4].
| Trial | Antibody | NCT Number | Phase | Enrollment | Duration | Status |
|---|---|---|---|---|---|---|
| CLARITY-AD | Lecanemab | NCT03887455 | Phase 3 | 1,795 | 18 months | Completed |
| TRAILBLAZER-ALZ 2 | Donanemab | NCT04437511 | Phase 3 | 1,736 | 18 months | Completed |
| GRADUATE-1/2 | Gantenerumab | NCT02051647, NCT03444870 | Phase 3 | ~3,000 | 2 years | Completed |
| A4 | Solanezumab | NCT02008357 | Phase 3 | 1,169 | 5 years | Completed |
| CLARITY OLE | Lecanemab | NCT05107146 | OLE | Ongoing | - | Ongoing |
| Parameter | Lecanemab (CLARITY-AD) | Donanemab (TRAILBLAZER-ALZ 2) | Gantenerumab (GRADUATE) | Solanezumab (A4) |
|---|---|---|---|---|
| Diagnosis | MCI due to AD, mild AD dementia | Early symptomatic AD (MCI or mild dementia) | Early AD (MCI or mild dementia) | Preclinical AD (cognitively normal) |
| Age | 50-90 years | 60-85 years | 50-90 years | 65-85 years |
| MMSE | 22-30 | 20-28 | 22-30 | 25-30 |
| Amyloid requirement | PET+ or CSF+ | PET+ | PET+ | PET+ |
| Tau requirement | Any | Low-to-medium tau | Any | Any |
| Notable exclusion | None | Excluded high tau | None | None |
Tau Selection: Donanemab's TRAILBLAZER-ALZ 2 specifically enrolled patients with low-to-medium tau pathology, excluding those with high tau burden. This enrichment strategy may have contributed to its stronger efficacy signals.
Disease Stage: The A4 trial enrolled cognitively normal individuals with preclinical AD, making it unique as a secondary prevention trial. All other trials focused on early symptomatic disease.
Treatment Duration: CLARITY-AD and TRAILBLAZER-ALZ 2 were 18-month trials, while GRADUATE was 2 years.
| Antibody | Primary Endpoint | Treatment Effect | Placebo Decline | Slowing | P-value |
|---|---|---|---|---|---|
| Lecanemab | CDR-SB | -0.45 | 1.66 | 27% | p=0.00005 |
| Donanemab | iADRS | -6.02 vs -10.36 | 10.36 | 35% | p<0.001 |
| Donanemab | CDR-SB | -1.72 | -2.42 | 29% | p<0.001 |
| Gantenerumab | CDR-SB | -0.31 | 2.04 | ~15% | p=0.0003 |
| Solanezumab | CDR-SB | No significant difference | - | - | Not significant |
| Antibody | Plaque Reduction (vs placebo) | Timepoint | Method |
|---|---|---|---|
| Lecanemab | ~70% SUVr reduction | 18 months | PET SUVr |
| Donanemab | 84% of patients achieved plaque clearance | 18 months | PET Centiloids |
| Gantenerumab | 59% reduction | 2 years | PET SUVr |
| Solanezumab | Minimal effect | 5 years | PET |
All antibodies that successfully removed amyloid plaques showed downstream biomarker effects:
ARIA is the most significant safety concern with anti-amyloid antibodies. It manifests as:
| Antibody | ARIA-E (treatment) | ARIA-E (placebo) | ARIA-H (treatment) | ARIA-H (placebo) |
|---|---|---|---|---|
| Lecanemab | 12.6% | 1.7% | 17.3% | 8.9% |
| Donanemab | 24.0% | 1.0% | 31.4% | 13.6% |
| Gantenerumab | 25% | 2% | 13% | 7% |
| Solanezumab | ~2% | ~1% | ~4% | ~3% |
| Adverse Event | Lecanemab | Donanemab | Gantenerumab |
|---|---|---|---|
| Infusion reactions | ~20% (mild/moderate) | ~8% | ~10% |
| Headache | Common | Common | Less common |
| Falls | Slightly increased | Similar to placebo | - |
| Discontinuation due to ARIA | ~3% | ~6% | ~5% |
Lecanemab (Leqembi):
Donanemab (Kisunla):
Based on trial data, patients most likely to benefit:
| Factor | Lecanemab | Donanemab | Gantenerumab | Solanezumab |
|---|---|---|---|---|
| FDA approved | Yes | Yes | No | No |
| Meaningful clinical benefit | Yes (27% slowing) | Yes (29-35% slowing) | Modest (~15%) | No |
| Robust plaque clearance | Yes (~70%) | Yes (84% cleared) | Yes (59%) | Minimal |
| Biomarker modification | Yes | Yes | Yes | No |
| Factor | Lecanemab | Donanemab | Gantenerumab |
|---|---|---|---|
| Dosing | Bi-weekly infusions | Monthly infusions | Monthly (escalating) |
| Titration period | Yes (5 doses) | Yes | Yes |
| Treatment discontinuation | Until progression | After plaque clearance | N/A (discontinued) |
| Monitoring intensity | Moderate | Higher (more ARIA) | Moderate |
van Dyck et al. Lecanemab in Early Alzheimer's Disease (2023). 2023. ↩︎
Sims et al. Donanemab in Early Alzheimer's Disease (2023). 2023. ↩︎
Bateman et al. Gantenerumab in Early Alzheimer's Disease (2023). 2023. ↩︎
Salloway et al. A4 Study: Solanezumab in Preclinical Alzheimer's Disease (2023). 2023. ↩︎